GlassScriptPhysician profile
Amanda A Littleton
NPI 1306324355
$3,635.66
in general payments reported to CMS, 2019-2025
44 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.71 · 2024: $1,603 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,374 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,373.67 |
| Education | $261.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $325.12 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $315.22 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $257.35 | 2024-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $230.78 | 2024-2025 | Opdivo, Opdualag, Eliquis |
| Janssen Biotech, INC. | $210.60 | 2024-2025 | Darzalex, Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals LP | $181.06 | 2024-2025 | Enhertu, Lynparza, Calquence |
| Lilly USA, LLC | $172.43 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Sobi, INC | $146.87 | 2024-2025 | |
| Pfizer INC. | $141.31 | 2024-2025 | |
| Genentech USA, INC. | $104.67 | 2024-2025 | Venclexta, Phesgo, Perjeta |
| Daiichi Sankyo INC. | $99.13 | 2024-2025 | Enhertu |
| Gilead Sciences, INC. | $87.16 | 2024-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.23 | 2024-2025 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $80.27 | 2024-2025 | Ultomiris |
| Seagen INC. | $77.99 | 2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Littleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.